Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography

Table 5 Pathology results in comparison to other methods of assessment

Patient	PIB-PET	Pathology	Criteria	FDG-Qual	FDG-Quant	MRI
2	-	CBD	fvCBS	tpvCBS	tpvCBS	fvCBS
3	-	CBD	fvCBS	fvCBS	fvCBS	fvCBS
8	-	CBD	tpvCBS	tpvCBS	tpvCBS	N/A
10	-	PSP	fvCBS	fvCBS	fvCBS	tpvCBS
14	-	Pick’s + DLB	tpvCBS	fvCBS	fvCBS	fvCBS
13	+	AD + CBD^a	tpvCBS	tpvCBS	tpvCBS	tpvCBS
18	+	AD + DLB	tpvCBS	tpvCBS	tpvCBS	tpvCBS
19	+	AD + DLB	tpvCBS	tpvCBS	tpvCBS	fvCBS

^aPatient 13 had evidence of AD and CBD pathology, but AD was the predominant pathology. AD, Alzheimer’s disease; CBD, corticobasal degeneration; fvCBS, frontal variant corticobasal syndrome; FDG-Qual, fluorodeoxyglucose PET qualitative (visual assessment); LBD, Lewy body disease; FDG-Quant, fluorodeoxyglucose PET quantitative (computed using ROI); PET, positron emission tomography; PSP, progressive supranuclear palsy; ROI, region of interest; tpvCBS, temporoparietal variant CBS. A ‘+’ or ‘-’ indicates positive or negative, respectively.

ISSN: 1758-9193